CAMBRIDGE, Mass.--(BUSINESS WIRE)--ViaCell, Inc. (Nasdaq: VIAC) today announced it has entered into an agreement with Invitrogen to manufacture its ViaCyteSM media. ViaCyte is ViaCell’s investigational product offering for use during assisted reproductive technology. The media manufactured by Invitrogen will be used in ViaCell’s pivotal clinical trial to evaluate the cryopreservation and thawing of human oocytes. Financial terms were not disclosed.
